UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Whole body PET/CT for initial staging of choroidal melanoma

British journal of ophthalmology, 2005-10, Vol.89 (10), p.1270-1274

2005

Volltextzugriff (PDF)

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6107-6116

2005

Volltextzugriff (PDF)

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

Annals of oncology, 2019-06, Vol.30 (6), p.927-933

2019

Volltextzugriff (PDF)

Primary choroidal melanoma followed by two metachronous ipsilateral ocular metastases

Rossiĭskiĭ oftalʹmologicheskiĭ zhurnal, 2022-03, Vol.15 (1), p.122-127

2022

Volltextzugriff (PDF)

Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors

Journal of clinical oncology, 1997-05, Vol.15 (5), p.1761-1766

1997

Volltextzugriff (PDF)

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

Annals of oncology, 2016-10, Vol.27, p.vi379-vi379

2016

Volltextzugriff (PDF)

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

Annals of oncology, 2016-10, Vol.27, p.vi381-vi381

2016

Volltextzugriff (PDF)

1318PPhase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Annals of oncology, 2016-10, Vol.27, p.vi393-vi393

2016

Volltextzugriff (PDF)

Multicenter, International Assessment of the Eighth Edition of the American Joint Committee on Cancer Cancer Staging Manual for Conjunctival Melanoma

JAMA ophthalmology, 2019-08, Vol.137 (8), p.905

2019

Volltextzugriff (PDF)

Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site

Neuro-oncology (Charlottesville, Va.), 2012-07, Vol.14 (7), p.849-858

2012

Volltextzugriff (PDF)

Novel therapeutic agents under investigation for malignant melanoma

Expert opinion on investigational drugs, 2003-09, Vol.12 (9), p.1545-1558

2003

Volltextzugriff (PDF)

Does incidence of rash predict treatment response to lapatanib in breast cancer?

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11127-e11127

2011

Volltextzugriff (PDF)

Abstract P4-15-05: Biomarkers of response to neoadjuvant endocrine therapy with anastrozole (Ana) alone or in combination with fulvestrant (Ful) in ER-positive (ER+) HER2-negative (HER2-) breast cancer (PACT01 trial)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-15-05

2019

Volltextzugriff (PDF)

Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8545-8545

2011

Volltextzugriff (PDF)

Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-09-12

2018

Volltextzugriff (PDF)

Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8540-8540

2011

Volltextzugriff (PDF)

Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8581-8581

2011

Volltextzugriff (PDF)

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8529-8529

2011

Volltextzugriff (PDF)

Impact of population genetic substructure on association studies and risk assessment for melanoma

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8521-8521

2011

Volltextzugriff (PDF)

Primary melanoma features associated with increased risk of brain metastasis

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8560-8560

2011

Volltextzugriff (PDF)

An analysis of sera-based microRNAs as biomarkers of recurrence in melanoma

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8513-8513

2011

Volltextzugriff (PDF)

Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8561-8561

2010

Volltextzugriff (PDF)

Prognostic factors for survival in patients with stage (stg) IV malignant melanoma (MM)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.9072-9072

2009

Volltextzugriff (PDF)

TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.505-505

2011

Volltextzugriff (PDF)

1 – 25 von 512

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(495)
Mit Volltextzugriff
(445)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Whole body PET/CT for initial staging of choroidal melanoma

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

Primary choroidal melanoma followed by two metachronous ipsilateral ocular metastases

Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

1318PPhase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Multicenter, International Assessment of the Eighth Edition of the American Joint Committee on Cancer Cancer Staging Manual for Conjunctival Melanoma

Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site

Novel therapeutic agents under investigation for malignant melanoma

Does incidence of rash predict treatment response to lapatanib in breast cancer?

Abstract P4-15-05: Biomarkers of response to neoadjuvant endocrine therapy with anastrozole (Ana) alone or in combination with fulvestrant (Ful) in ER-positive (ER+) HER2-negative (HER2-) breast cancer (PACT01 trial)

Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH)

Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer

Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations

Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study

Impact of population genetic substructure on association studies and risk assessment for melanoma

Primary melanoma features associated with increased risk of brain metastasis

An analysis of sera-based microRNAs as biomarkers of recurrence in melanoma

Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma

Prognostic factors for survival in patients with stage (stg) IV malignant melanoma (MM)

TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer

Suchergebnisse filtern